Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

de Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK.

Future Oncol. 2019 Jul 24. doi: 10.2217/fon-2019-0324. [Epub ahead of print]

PMID:
31339357
2.

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.

Ricciuti B, Brambilla M, Cortellini A, De Giglio A, Ficorella C, Sidoni A, Bellezza G, Crinò L, Ludovini V, Baglivo S, Metro G, Chiari R.

Clin Transl Oncol. 2019 Jul 22. doi: 10.1007/s12094-019-02175-y. [Epub ahead of print]

PMID:
31332704
3.

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Conte AD, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S.

Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27.

PMID:
31319983
4.

Phase II study of weekly carboplatin in pretreated adult malignant gliomas.

Villani V, Pace A, Vidiri A, Tanzilli A, Sperati F, Terrenato I, Mariantonia C, Casini B, Metro G, Maschio M, Tatiana K, Cognetti F, Fabi A.

J Neurooncol. 2019 Aug;144(1):211-216. doi: 10.1007/s11060-019-03223-x. Epub 2019 Jul 4.

PMID:
31273578
5.

Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM).

Facchinetti F, Pilotto S, Metro G, Baldini E, Bertolaccini L, Cappuzzo F, Delmonte A, Gasparini S, Inno A, Marchetti A, Passiglia F, Puma F, Ricardi U, Rossi A, Crinò L, Novello S.

Tumori. 2019 Jul;105(5_suppl):3-14. doi: 10.1177/0300891619857418.

PMID:
31264531
6.

Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma.

Chen R, Xia W, Wang S, Xu Y, Ma Z, Xu W, Zhang E, Wang J, Fang T, Zhang Q, Dong G, Cho WC, Ma PC, Brandi G, Tavolari S, Ujhazy P, Metro G, Popper HH, Yin R, Qiu M, Xu L.

Mol Ther Nucleic Acids. 2019 Jun 7;16:543-553. doi: 10.1016/j.omtn.2019.04.004. Epub 2019 Apr 13.

7.
8.

Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.

Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G, Baglivo S, Dal Bello MG, Ceribelli A, Grossi F, Chiari R.

Clin Lung Cancer. 2019 May;20(3):178-185.e2. doi: 10.1016/j.cllc.2019.02.001. Epub 2019 Feb 27.

PMID:
30910574
9.

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.

Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.

Clin Lung Cancer. 2019 Jul;20(4):237-247.e1. doi: 10.1016/j.cllc.2019.02.006. Epub 2019 Feb 21.

PMID:
30885550
10.

Early stage resectable non-small cell lung cancer: is neoadjuvant immunotherapy the right way forward?

Chiari R, Sidoni A, Metro G.

J Thorac Dis. 2018 Nov;10(Suppl 33):S3890-S3894. doi: 10.21037/jtd.2018.10.22. No abstract available.

11.

KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer.

Ludovini V, Ricciuti B, Tofanetti FR, Mencaroni C, Giannarelli D, Sidoni A, Reda MS, Siggillino A, Baglivo S, Crinò L, Bellezza G, Chiari R, Metro G.

Mol Clin Oncol. 2018 Dec;9(6):689-696. doi: 10.3892/mco.2018.1731. Epub 2018 Oct 1.

12.

Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.

Ricciuti B, Genova C, De Giglio A, Bassanelli M, Dal Bello MG, Metro G, Brambilla M, Baglivo S, Grossi F, Chiari R.

J Cancer Res Clin Oncol. 2019 Feb;145(2):479-485. doi: 10.1007/s00432-018-2805-3. Epub 2018 Dec 1.

PMID:
30506406
13.

Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications.

Mandarano M, Bellezza G, Belladonna ML, Van den Eynde BJ, Chiari R, Vannucci J, Mondanelli G, Ludovini V, Ferri I, Bianconi F, Del Sordo R, Cagini L, Albini E, Metro G, Puma F, Sidoni A.

Virchows Arch. 2019 Feb;474(2):159-168. doi: 10.1007/s00428-018-2483-1. Epub 2018 Nov 17.

PMID:
30448912
14.

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Metro G, Di Maio M.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S294-S296. doi: 10.21037/tlcr.2018.07.12. No abstract available.

15.

Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Metro G, Di Maio M.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S290-S293. doi: 10.21037/tlcr.2018.07.11. No abstract available.

16.

Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib.

Ricciuti B, Marcomigni L, Metro G, Bellezza G, Caselli E, Baglivo S, Chiari R.

J Thorac Oncol. 2018 Nov;13(11):e220-e222. doi: 10.1016/j.jtho.2018.05.035. No abstract available.

PMID:
30368411
17.

Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient.

Metro G, Baglivo S, Siggillino A, Ludovini V, Chiari R, Rebonato A, Bellezza G.

Clin Drug Investig. 2018 Oct;38(10):983-987. doi: 10.1007/s40261-018-0691-8.

PMID:
30151614
18.

Osimertinib.

Malapelle U, Ricciuti B, Baglivo S, Pepe F, Pisapia P, Anastasi P, Tazza M, Sidoni A, Liberati AM, Bellezza G, Chiari R, Metro G.

Recent Results Cancer Res. 2018;211:257-276. doi: 10.1007/978-3-319-91442-8_18. Review.

PMID:
30069773
19.

Dramatic Response to Lorlatinib in a Heavily Pretreated Lung Adenocarcinoma Patient Harboring G1202R Mutation and a Synchronous Novel R1192P ALK Point Mutation.

Baglivo S, Ricciuti B, Ludovini V, Metro G, Siggillino A, De Giglio A, Chiari R.

J Thorac Oncol. 2018 Aug;13(8):e145-e147. doi: 10.1016/j.jtho.2018.03.017. No abstract available.

20.

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?

Addeo A, Metro G.

Drugs Context. 2018 Jul 10;7:212537. doi: 10.7573/dic.212537. eCollection 2018.

21.

EGFR targeted therapy for lung cancer: are we almost there?

Metro G.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S142-S145. doi: 10.21037/tlcr.2018.03.11. No abstract available.

22.

Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations.

Ricciuti B, Baglivo S, Ludovini V, Sidoni A, Metro G, Brambilla M, Siggillino A, Reda MS, Rebonato A, Maiettini D, Chiari R.

Lung Cancer. 2018 Jun;120:70-74. doi: 10.1016/j.lungcan.2018.04.002. Epub 2018 Apr 3.

PMID:
29748019
23.

Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients.

Metro G, Giannarelli D, Sidoni A, Chiari R, Bellezza G.

Int J Biol Markers. 2018 Apr 1:1724600818754763. doi: 10.1177/1724600818754763. [Epub ahead of print] No abstract available.

PMID:
29683065
24.

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib.

Ricciuti B, De Giglio A, Mecca C, Arcuri C, Marini S, Metro G, Baglivo S, Sidoni A, Bellezza G, Crinò L, Chiari R.

Med Oncol. 2018 Apr 17;35(5):72. doi: 10.1007/s12032-018-1133-4. Review.

PMID:
29666949
25.

Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter?

De Giglio A, Porreca R, Brambilla M, Metro G, Prosperi E, Bellezza G, Pirro M, Chiari R, Ricciuti B.

Thromb Res. 2018 Mar;163:51-53. doi: 10.1016/j.thromres.2017.12.004. Epub 2017 Dec 9. No abstract available.

PMID:
29353684
26.

Adjuvant treatment of non-small cell lung cancer: focus on targeted therapy.

Tazza M, Metro G.

J Thorac Dis. 2017 Oct;9(10):4064-4069. doi: 10.21037/jtd.2017.08.130. Review.

27.

Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.

Ricciuti B, Metro G, Brambilla M, Ludovini V, Baglivo S, Siggillino A, Prosperi E, Chiari R.

J Thorac Oncol. 2018 Jan;13(1):e9-e12. doi: 10.1016/j.jtho.2017.08.025. No abstract available.

28.

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

Metro G, Passaro A, Lo Russo G, Bonanno L, Giusti R, Gregorc V, Capelletto E, Martelli O, Cecere FL, Giannarelli D, Luciani A, Bearz A, Tuzi A, Scotti V, Tonini G, Galetta D, Carta A, Soto Parra H, Rebonato A, Morabito A, Chiari R.

Future Oncol. 2018 Feb;14(4):353-361. doi: 10.2217/fon-2017-0441. Epub 2017 Nov 14.

PMID:
29135281
29.

Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma.

Bellezza G, Vannucci J, Bianconi F, Metro G, Del Sordo R, Andolfi M, Ferri I, Siccu P, Ludovini V, Puma F, Sidoni A, Cagini L.

Interact Cardiovasc Thorac Surg. 2017 Dec 1;25(6):856-861. doi: 10.1093/icvts/ivx202.

PMID:
29106595
30.

Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.

Rebonato A, Graziosi L, Maiettini D, Marino E, De Angelis V, Brunese L, Mosca S, Metro G, Rossi M, Orgera G, Scialpi M, Donini A.

Gastroenterol Res Pract. 2017;2017:4164130. doi: 10.1155/2017/4164130. Epub 2017 Aug 15.

31.

Erratum to: CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles.

Rebonato A, Maiettini D, Andolfi M, Fischer MJ, Vannucci J, Metro G, Basile A, Duranti M, Rossi M.

Cardiovasc Intervent Radiol. 2018 Jan;41(1):202. doi: 10.1007/s00270-017-1781-3. No abstract available.

PMID:
28861589
32.

CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles.

Rebonato A, Maiettini D, Andolfi M, Fischer MJ, Vannucci J, Metro G, Basile A, Rossi M, Duranti M.

Cardiovasc Intervent Radiol. 2018 Feb;41(2):284-290. doi: 10.1007/s00270-017-1768-0. Epub 2017 Aug 14. Erratum in: Cardiovasc Intervent Radiol. 2017 Aug 31;:.

PMID:
28808757
33.

Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.

Baglivo S, Ludovini V, Sidoni A, Metro G, Ricciuti B, Siggillino A, Rebonato A, Messina S, Crinò L, Chiari R.

Mayo Clin Proc. 2017 Aug;92(8):1304-1311. doi: 10.1016/j.mayocp.2017.03.022.

PMID:
28778263
34.

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy.

Ricciuti B, Baglivo S, Paglialunga L, De Giglio A, Bellezza G, Chiari R, Crinò L, Metro G.

Ther Adv Med Oncol. 2017 Jun;9(6):387-404. doi: 10.1177/1758834017702820. Epub 2017 Apr 16. Review.

35.

Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.

Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, Picasso V, Massari F, Gori S.

Tumori. 2017 Sep 18;103(5):405-421. doi: 10.5301/tj.5000625. Epub 2017 May 10. Review.

PMID:
28497847
36.

Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence.

Ricciuti B, Brambilla M, Metro G, Baglivo S, Matocci R, Pirro M, Chiari R.

Med Oncol. 2017 Jun;34(6):105. doi: 10.1007/s12032-017-0967-5. Epub 2017 Apr 25. Review.

PMID:
28444624
37.

Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.

Ricciuti B, Metro G, Baglivo S, Colabrese D, Chiari R, Bennati C, Paglialunga L.

J Thorac Oncol. 2017 May;12(5):e51-e55. doi: 10.1016/j.jtho.2016.12.027. No abstract available.

38.

Optimal management of ALK-positive NSCLC progressing on crizotinib.

Metro G, Tazza M, Matocci R, Chiari R, Crinò L.

Lung Cancer. 2017 Apr;106:58-66. doi: 10.1016/j.lungcan.2017.02.003. Epub 2017 Feb 6. Review.

PMID:
28285695
39.

Preface on "Emerging treatment options for brain metastases from non-small cell lung cancer".

Metro G, Chiari R.

Transl Lung Cancer Res. 2016 Dec;5(6):561-562. doi: 10.21037/tlcr.2016.12.04. No abstract available.

40.

Sacrum colon-rectal cancer metastasis: microwave ablation for palliative pain treatment.

Maiettini D, De Angelis V, Graziosi L, Rebonato S, Falcinelli L, Metro G, Rebonato A.

Recenti Prog Med. 2016 Dec;107(12):673-676. doi: 10.1701/2502.26238.

PMID:
27997010
41.

The safety of nivolumab for the treatment of advanced non-small cell lung cancer.

Metro G, Ricciuti B, Brambilla M, Baglivo S, Soli I, Minenza E, Leonardi GC, D'arpino A, Colabrese D, Tazza M, Zicari D, Minotti V, Chiari R.

Expert Opin Drug Saf. 2017 Jan;16(1):101-109. Epub 2016 Dec 11. Review.

PMID:
27910704
42.

Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland.

Ricciuti B, Metro G, Leonardi GC, Sordo RD, Colella R, Puma F, Ceccarelli S, Potenza R, Rebonato A, Maiettini D, Crinò L, Chiari R.

Tumori. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000514.

PMID:
27133228
43.

Ductal Breast Carcinoma Metastatic to the Stomach Resembling Primary Linitis Plastica in a Male Patient.

Ricciuti B, Leonardi GC, Ravaioli N, De Giglio A, Brambilla M, Prosperi E, Ribacchi F, Meacci M, Crinò L, Maiettini D, Chiari R, Metro G.

J Breast Cancer. 2016 Sep;19(3):324-329. Epub 2016 Sep 23.

44.

How might treatment of ALK-positive non-small cell lung cancer change in the near future?

Metro G, Bellezza G, Puma F, Chiari R.

Expert Rev Anticancer Ther. 2016 Oct;16(10):997-9. doi: 10.1080/14737140.2016.1226138. Epub 2016 Aug 25. No abstract available.

PMID:
27534579
45.

Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.

Metro G, Lunardi G, Bennati C, Chiarini P, Sperduti I, Ricciuti B, Marcomigni L, Costa C, Crinò L, Floridi P, Gori S, Chiari R.

J Neurooncol. 2016 Sep;129(2):355-61. doi: 10.1007/s11060-016-2184-z. Epub 2016 Jun 20.

PMID:
27324494
46.

Targeting EGFR and ALK in NSCLC: current evidence and future perspective.

Bennati C, Paglialunga L, Ricciuti B, Metro G, Marcomigni L, Gili A, Crinò L.

Lung Cancer Manag. 2016 Jun;5(2):79-90. doi: 10.2217/lmt-2016-0005. Epub 2016 Jun 23. Review.

47.

Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.

Ricciuti B, Chiari R, Chiarini P, Crinò L, Maiettini D, Ludovini V, Metro G.

Clin Drug Investig. 2016 Aug;36(8):683-6. doi: 10.1007/s40261-016-0411-1.

PMID:
27177916
48.

Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis.

Ludovini V, Bianconi F, Siggillino A, Piobbico D, Vannucci J, Metro G, Chiari R, Bellezza G, Puma F, Della Fazia MA, Servillo G, Crinò L.

Oncotarget. 2016 May 24;7(21):30561-74. doi: 10.18632/oncotarget.8723.

49.

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.

Metro G, Ricciuti B, Chiari R, Baretti M, Falcinelli L, Giannarelli D, Sidoni A, Mountzios G, Crinò L, Bellezza G, Rebonato A, Ferolla P, Toschi L.

Lung Cancer. 2016 May;95:82-7. doi: 10.1016/j.lungcan.2016.03.006. Epub 2016 Mar 15.

PMID:
27040856
50.

Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy.

Ricciuti B, Mencaroni C, Paglialunga L, Paciullo F, Crinò L, Chiari R, Metro G.

Med Oncol. 2016 Feb;33(2):18. doi: 10.1007/s12032-016-0731-2. Epub 2016 Jan 19. Review.

PMID:
26786153

Supplemental Content

Support Center